Sugar, We’re Going Down: Navigating Glycemic Control in the Era of PI3K/AKT Inhibition for Breast Cancer

Program Description

Hyperglycemia is one of the most common and clinically significant adverse effects associated with PI3K/AKT inhibitors used in the treatment of hormone receptor-positive (HR+), HER2-negative breast cancer. With up to 80% of patients affected, this complication poses a substantial barrier to optimal therapy and can lead to dose reductions, treatment interruptions, or discontinuation. Proactive monitoring and early intervention are essential to reducing the risk and severity of hyperglycemia in patients receiving these therapies. This activity will equip oncology pharmacists with the clinical insights and practical strategies needed to recognize, prevent, and manage PI3K/AKT inhibitor-induced hyperglycemia. Differences in agent-specific glycemic toxicity, evidence-based prophylactic and management approaches, and interdisciplinary protocols that support continuity of cancer care will be highlighted. Through expert-led discussion of patient cases, participants will gain actionable strategies to minimize treatment disruption and improve outcomes for patients with breast cancer.

Target Audience: Oncology Pharmacist

Type of Activity: Application
Release date: December 5, 2025
Expiration date: December 5, 2026
Learner level: Foundational, Intermediate
Time to complete activity: 1.0 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Analyze patterns of hyperglycemia associated with specific PI3K/AKT pathway inhibitors to inform breast cancer treatment decisions.
• Apply proactive monitoring and intervention strategies to reduce the risk and severity of hyperglycemia in patients receiving PI3K/AKT pathway inhibitors.
• Explore supportive care strategies to proactively address hyperglycemia in patients receiving PI3K/AKT inhibitors and minimize treatment disruptions.

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.10 CEU) under the ACPE universal activity number 0290-0000-25-396-H05-P. The activity is available for CE credit through December 5, 2026.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

The following contributors have no relevant financial relationships with ineligible companies to disclose:

Faculty

Jordan Hill, PharmD, BCOP

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Daphne Davis, PharmD, BCOP; Victoria Chirdo; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with ineligible companies to disclose.

Any relevant financial relationships listed for these individuals have been mitigated.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Educational Disclaimer

CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms